How to appeal a Humana adult car-t cell therapy denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for adult car-t cell therapy

Cited policy: Humana Medical Coverage Policy — Idecabtagene Vicleucel (Abecma)

FDA-approved indication: r/r multiple myeloma after >=2 prior lines including IMiD + PI + anti-CD38 mAb (Apr 2024 2L+ expansion via KarMMa-3) OR after >=4 prior lines (Mar 2021). Age >=18. ECOG 0-1. LVEF >=45%, CrCl >=45, AST/ALT <2.5x ULN, total bili <1.5x ULN, ANC >=1000, plt >=50K. No prior BCMA-directed CAR-T. Administered at FACT-accredited REMS-certified ATC. Bridging + Flu/Cy LD (Flu 30 + Cy 300 mg/m² x 3 d) bundled.

How Humana denies adult car-t cell therapy — and how to counter it

Where Humana pushes back: 1) 'Carvykti preferred over Abecma'; 2) Insufficient prior IMiD + PI + anti-CD38 documentation; 3) Triple-class refractory documentation strict-interpretation; 4) Bridging therapy denied separately.

Counter-arguments that hold up: KarMMa-3 (Rodriguez-Otero NEJM 2023;388:1002) — Abecma vs SOC standard regimens in 2L+ triple-class-exposed MM with PFS HR 0.49 → FDA Apr 4 2024 2L+ expansion. NCCN MM v3.2024 lists both Abecma and Carvykti as 2L+ options; product choice is per treating physician + slot availability + apheresis logistics — payer cannot mandate one BCMA CAR-T over another. KarMMa-3 entry required prior IMiD + PI + anti-CD38 with refractoriness to last regimen — matches Apr 2024 label exactly. Bridging is inherent to CAR-T pathway per NCCN MM v3.2024 + ASTCT 2024 consensus. CMS NCD 110.24 covers FDA-approved indications.

What Humana typically denies for adult car-t cell therapy

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For adult car-t cell therapy, expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the adult car-t cell therapy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Yescarta
• Kymriah
• Tecartus
• Breyanzi
• Carvykti
• Abecma

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.